Mandana Ahmadian
Endocrinology, Diabetes & Metabolism · Bellevue, WANPI 1164473914
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.
Across 257 payments — averaging $32.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$867
- AstraZeneca$759
- Lilly USA, LLC$518
- Antares Pharma, Inc.$489
- Sanofi-aventis U.S. LLC$419
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,23799%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,683 |
| Amgen(2 entities) | 14 | $867 |
| AstraZeneca(2 entities) | 24 | $759 |
| Lilly USA, LLC | 22 | $518 |
| Antares Pharma, Inc. | 22 | $489 |
| Sanofi-aventis U.S. LLC | 9 | $419 |
| Boehringer Ingelheim | 18 | $412 |
| Tandem Diabetes Care, Inc. | 11 | $391 |
| Medtronic | 4 | $351 |
| Ascendis Pharma Endocrinology Inc | 8 | $345 |
| Bigfoot Biomedical Inc | 2 | $239 |
| Xeris Pharmaceuticals, Inc. | 5 | $213 |
| Dexcom, Inc. | 8 | $196 |
| IBSA Pharma Inc. | 4 | $175 |
| Corcept Therapeutics | 3 | $144 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Lifescan, Inc. | 6 | $118 |
| Radius Health, Inc. | 5 | $108 |
| Acella Pharmaceuticals, LLC | 2 | $89 |
| Exelixis Inc. | 1 | $87 |
| Insulet Corporation | 3 | $86 |
| Johnson & Johnson | 5 | $86 |
| Recordati_rare_diseases_inc. | 1 | $72 |
| Neurocrine Biosciences, Inc. | 3 | $68 |
| Merck | 3 | $51 |
| Bayer | 2 | $34 |
| Echosens North America, Inc. | 1 | $31 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,288 in reported general payments places this provider in the 80th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $6,945 |
| SynthroidLevothyroxine Sodium | 11 | $1,270 |
| Levothyroxine Sodium | 84 | $573 |
| Rosuvastatin Calcium | 13 | $337 |
| Metformin Hcl | 11 | $150 |
| Ezetimibe | 11 | $148 |
| Alendronate Sodium | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Bellevue
- Deborah GolobBellevue$4K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Bruce WilsonRichland$352K
- Irl HirschSeattle$192K
- Biju KunhiramanYakima$118K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.